Compare HURN & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HURN | IRON |
|---|---|---|
| Founded | 2002 | 2017 |
| Country | United States | United States |
| Employees | N/A | 155 |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.3B |
| IPO Year | 2004 | 2020 |
| Metric | HURN | IRON |
|---|---|---|
| Price | $124.94 | $59.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 11 |
| Target Price | ★ $215.50 | $103.18 |
| AVG Volume (30 Days) | 292.4K | ★ 520.9K |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 5.84 | N/A |
| Revenue | ★ $1,699,143,000.00 | N/A |
| Revenue This Year | $11.74 | N/A |
| Revenue Next Year | $10.55 | $283.52 |
| P/E Ratio | $22.27 | ★ N/A |
| Revenue Growth | ★ 11.65 | N/A |
| 52 Week Low | $116.12 | $30.82 |
| 52 Week High | $186.78 | $99.50 |
| Indicator | HURN | IRON |
|---|---|---|
| Relative Strength Index (RSI) | 34.33 | 41.05 |
| Support Level | $118.18 | $57.81 |
| Resistance Level | $138.06 | $61.93 |
| Average True Range (ATR) | 4.92 | 2.67 |
| MACD | 0.09 | 0.19 |
| Stochastic Oscillator | 1.08 | 24.93 |
Huron Consulting Group Inc is a professional services firm. The company provides expertise in technology, operations, advisory services, & analytics through three operating segments namely Healthcare, Education, and Commercial. Healthcare segment helps the firms to transform and innovate the delivery model to focus on patient wellness by improving quality outcomes, minimizing care variation and fundamentally improving patient and population health, Education segment provides management consulting and technology solutions, and Commercial segment is focused on serving industries and organizations facing disruption and regulatory change. It generates a majority of its revenue from the Healthcare Segment.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.